tbuckley/cabot-search huggingface dataset:
The use of subcutaneous natural ghrelin to treat cachexia (CC)-related symptom distress, nutritional intake (NI), and physical functioning: A two-step phase I/II study with an intrapatient dose escalation followed by maintenance treatment.
Authors: F. Strasser, D. Blum, R. Oberholzer, S. deWolf-Linder, C. Driessen, T. Cerny
Journal: Journal of Clinical Oncology (2011)

TPS234 Background: CC is a frequent and distressing syndrome, updated by us and others for definition, diagnosis, classification (Lancet Oncology 2011) and mechanisms (CRHO 2011), abnormal (muscle) metabolism, inflammation, gut-brain nutritional dysregulation. Natural ghrelin, a peptide growth hormone secretagogue, stimulates NI, gastrointestinal motility and a positive energy balance. We reported the safety and tolerability of an 1-hour i.v. infusion of ghrelin (2mg and 8mg/kg BW) from a double-blind, placebo-controlled, intra-patient double crossover study (BJC 2008). We designed this trial to identify the individual dose to improve NI, eating-related symptoms (ERS), muscle mass and strength. Methods: Patients with CC despite standard cachexia management (multidimensional symptom control, nutritional, physical therapy, psychosocial), with unchanged (>4 weeks) or no systemic anti-neoplastic treatment, normal cognition, and PS≤2, are eligible. Titration starts with 32 μg/kgBW (iv-data, 25% bioavailability s.c.), then 50% increase per dose level, peak levels (GH, ghrelin) are measured at 45 minutes. Patients inject s.c. ghrelin for each dose level bi-daily for 2 days followed by 1-2 days wash-out, at days 1, 4, etc. as outpatients before monitored lunch. The composite 1° endpoint (EP) is a) Minimal Dose for Maximal Nutritional Intake: ≥10% NI increase [2 days food diaries, scales at home] reaching a plateau, and b) improved ERS [9 items before & after injection], and c) positive narratives (content analysis) from patients/proxies, or when MTD is reached. During maintenance patients inject 10 doses per week s.c. (≤2 per day), one as outpatient. The composite 1° EP is handgrip strenght ≥4kg and muscle mass (CT-scan L3/4 or DEXA; 2%). Additional EPs are physical function (get-up-and-go, 10-step stair climb, ActivPal [6 days]), symptoms (ESAS, FAACT, HADS-D, EORTC QLQ 30), gastrointestinal motility (Radio Opaque Markers, 4 hours), inflammation (serum CRP, IL-6, TNFa), safety and s.c. tolerability (VAS). Treatment duration is 6 weeks. 20 pts are planned, 10 accrued.
Parallel Signaling through PI3K/AKT/mTOR Mediates Resistance to MEK Inhibition in Preclinical Models of Acute Myeloid Leukemia (AML): Synergistic Effects of Combined MEK and mTOR Inhibition.
Authors: Maria Rosaria Ricciardi, Twee Tsao, Stephen Lee Abrams, Paola Bergamo, Linda S Steelman, Samantha Decandia, Lara Felicioni, Ludovica Ciuffreda, Cristina Di Sanza, Antonio Marchetti, Francesco Cognetti, James McCubrey, Marina Konopleva, Michael Andreeff, Agostino Tafuri, Michele Milella
Journal: Blood (2009)
A Randomized Study of Low Dose Oral Clofarabine 10 Mg Versus 20 Mg (flat dose) Daily × 5 for Patients with Higher-Risk Myelodysplastic Syndrome (MDS)
Authors: Stefan Faderl, Guillermo Garcia-Manero, Farhad Ravandi, Jorge E. Cortes, Zeev Estrov, Gautam Borthakur, Susan M. O'Brien, Tapan M. Kadia, Marina Konopleva, Naval Daver, Mark Brandt, Heather Schroeder, Hagop M. Kantarjian
Journal: Blood (2012)
P1.01-054 Lung Cancer: Histology, Gender and Age Changes Over Past 30 Years in Brazil
Authors: Maria Teresa Ruiz Tsukazan, Álvaro Vigo, Vinícius Duval Da Silva, Flávio Cabral, Renata Rosenthal, Arthur Vieira, Jayme Rios, José Antônio Figueiredo Pinto
Journal: Journal of Thoracic Oncology (2017)
Multiple-Instance Learning for Medical Image and Video Analysis
Authors: Gwenole Quellec, Guy Cazuguel, Beatrice Cochener, Mathieu Lamard
Journal: IEEE Reviews in Biomedical Engineering (2017)

Multiple-instance learning (MIL) is a recent machine-learning paradigm that is particularly well suited to medical image and video analysis (MIVA) tasks. Based solely on class labels assigned globally to images or videos, MIL algorithms learn to detect relevant patterns locally in images or videos. These patterns are then used for classification at a global level. Because supervision relies on global labels, manual segmentations are not needed to train MIL algorithms, unlike traditional single-instance learning (SIL) algorithms. Consequently, these solutions are attracting increasing interest from the MIVA community: since the term was coined by Dietterich et al. in 1997, 73 research papers about MIL have been published in the MIVA literature. This paper reviews the existing strategies for modeling MIVA tasks as MIL problems, recommends general-purpose MIL algorithms for each type of MIVA tasks, and discusses MIVA-specific MIL algorithms. Various experiments performed in medical image and video datasets are compiled in order to back up these discussions. This meta-analysis shows that, besides being more convenient than SIL solutions, MIL algorithms are also more accurate in many cases. In other words, MIL is the ideal solution for many MIVA tasks. Recent trends are discussed, and future directions are proposed for this emerging paradigm.
Somatic Mutations and Polymorphisms of the Glucocorticoid Receptor Gene Are Not Related to Glucocorticoid Resistance in Childhood ALL.
Authors: Wim Tissing, Jules P.P. Meijerink, Monique L. Den Boer, Bas Brinkhof, Liesbeth van Rossum, Elisabeth R. van Wering, Jan Willem Koper, Pieter Sonneveld, Rob Pieters
Journal: Blood (2004)
OA06.07 Evaluating Genomic Signatures Predicting Veliparib Sensitivity in Non-Small Cell Lung Cancer (NSCLC)
Authors: Lei He, Xin Huang, Yan Sun, Vasudha Sehgal, Xin Lu, Fang Jiang, Paul Jung, Youping Deng, Joann Palma, Anahita Bhathena, Peter Ansell, Mark Mckee
Journal: Journal of Thoracic Oncology (2017)
P3.03-055 Results of Second-Line Chemotherapy in Pleural Mesothelioma: A Single-Centre, Retrospective Study
Authors: Juan Carlos Pardo Ruiz, Yolanda Garcia Garcia, Paula Ribera Fernandez, Maria Marin Alcala, Marta Ferrer Cardona, Helena Oliveres Montero De Novoa, Clara Martinez Vila, Jose Manuel Cabrera Romero, Julia Giner Joaquin, Ismael Macias Declara, Elsa Dalmau Portulas, Eugeni Saigi Grau
Journal: Journal of Thoracic Oncology (2017)
No Influence on the Incidence of Osteonecroses When Dexamethasone Replaces Prednisone during Induction Treatment for Childhood ALL: Results of Trial ALL-BFM 2000.
Authors: Anja Möricke, Martin Zimmermann, Andre Schrauder, Martin Stanulla, Hansjörg Schmid, Rüdiger Fengler, Michael Frühwald, Georg Mann, Martin Schrappe
Journal: Blood (2008)
Phase I Study of 131-I-Tositumomab Radioimmunotherapy (RIT) in Patients with Relapsed or Residual CD20 Antigen-Expressing B Cell Lymphomas Following Autologous Hematopoietic Stem Cell Transplantation
Authors: Yang Liu, Elise A. Chong, Sigrid Berg, Abass Alavi, Rodolfo Perini, Jakub Svoboda, Sunita Dwivedy Nasta, Anthony Mato, Stephen J. Schuster
Journal: Blood (2014)
OA19.05 High Oncofetal Chondroitin Sulfate Expression is an Independent Prognostic Factor of Poor Survival in Early-Stage NSCLC
Authors: Zoltan Lohinai, Htoo Oo, Gunjan Kumar, Jeffrey Allen, Nhan Tran, Balazs Dome, Judit Moldvay, Glen Weiss, Mads Daugaard
Journal: Journal of Thoracic Oncology (2017)
OA06.01 Clinical Utility of Circulating Tumor DNA (ctDNA) Analysis by Digital next Generation Sequencing of over 5,000 Advanced NSCLC Patients
Authors: Philipp Mack, Kimberly Banks, Jonathan Riess, Oliver Zill, Stefanie Mortimer, Darya Chudova, Justin Odegaard, Christine Lee, Rebecca Nagy, Helmy Eltoukhy, Amirali Talasaz, Richard Lanman, David R. Gandara
Journal: Journal of Thoracic Oncology (2017)
P3.01-031 Impact of a Novel Lung Gross Dissection Method on Intrapulmonary Lymph Node Yield
Authors: G. Spencer, Matthew Smeltzer, Nicholas Faris, Carrie Fehnel, Cheryl Houston-Harris, Meredith Ray, Clara Finch-Cruz, Allen Berry, Chris Gianpapa, Holly Hilsenbeck, Elizabeth Sales, Robert Jarrett, Raymond Osarogiagbon
Journal: Journal of Thoracic Oncology (2017)
P2.03b-033 Clinical Effectiveness of Hybrid Capture-Based Massive Parallel Sequencing in Therapeutic Strategy Planning in Lung Cancer
Authors: Anna Belilovski Rozenblum, Maya Ilouze, Elizabeth Dudnik, Addie Dvir, Lior Soussan-Gutman, Smadar Geva, Nir Peled
Journal: Journal of Thoracic Oncology (2017)
P2.04-042 Epithelial-Myoepithelial Tumor of Unknown Origin: An Interesting Case Report with Unexpected Outcome
Authors: Nektarios Alevizopoulos, Ioanna Sigala, Theodoros Tegos, Areti Dimitriadou, Theodoros Vagdatlis, Anna Skoula, Vasiliki Ntalapera, Nickie Loukas, Michael Vaslamatzis
Journal: Journal of Thoracic Oncology (2017)
Renal Collectrin Protects against Salt-Sensitive Hypertension and Is Downregulated by Angiotensin II
Authors: Pei-Lun Chu, Joseph C. Gigliotti, Sylvia Cechova, Gabor Bodonyi-Kovacs, Fang Chan, Donna Lee Ralph, Nancy Howell, Kambiz Kalantari, Alexander L. Klibanov, Robert M. Carey, Alicia A. McDonough, Thu H. Le
Journal: Journal of the American Society of Nephrology (2017)

Collectrin, encoded by the Tmem27 gene, is a transmembrane glycoprotein with approximately 50% homology with angiotensin converting enzyme 2, but without a catalytic domain. Collectrin is most abundantly expressed in the kidney proximal tubule and collecting duct epithelia, where it has an important role in amino acid transport. Collectrin is also expressed in endothelial cells throughout the vasculature, where it regulates L-arginine uptake. We previously reported that global deletion of collectrin leads to endothelial dysfunction, augmented salt sensitivity, and hypertension. Here, we performed kidney crosstransplants between wild-type (WT) and collectrin knockout ( Tmem27Y/- ) mice to delineate the specific contribution of renal versus extrarenal collectrin on BP regulation and salt sensitivity. On a high-salt diet, WT mice with Tmem27Y/- kidneys had the highest systolic BP and were the only group to exhibit glomerular mesangial hypercellularity. Additional studies showed that, on a high-salt diet, Tmem27Y/- mice had lower renal blood flow, higher abundance of renal sodium-hydrogen antiporter 3, and lower lithium clearance than WT mice. In WT mice, administration of angiotensin II for 2 weeks downregulated collectrin expression in a type 1 angiotensin II receptor–dependent manner. This downregulation coincided with the onset of hypertension, such that WT and Tmem27Y/- mice had similar levels of hypertension after 2 weeks of angiotensin II administration. Altogether, these data suggest that salt sensitivity is determined by intrarenal collectrin, and increasing the abundance or activity of collectrin may have therapeutic benefits in the treatment of hypertension and salt sensitivity.
PL03.09: Phase 3 Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, with Docetaxel versus Docetaxel in Advanced Non-Small Cell Lung Cancer (GALAXY-2)
Authors: Rathi Pillai, Dean Fennell, Vladimir Kovcin, Tudor Ciuleanu, Rodryg Ramlau, Dariusz Kowalski, Michael Schenker, Branislav Perin, Ilker Yalcin, Florentina Teofilovici, Vojo Vukovic, Suresh Ramalingam
Journal: Journal of Thoracic Oncology (2017)
OA09.06 Metformin Use during Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Authors: Krista Wink, José Belderbos, Edith Dieleman, Maddalena Rossi, Coen Rasch, Ronald Damhuis, Ruud Houben, Esther Troost
Journal: Journal of Thoracic Oncology (2017)
A Conference of New Ideas in Cancer—Challenging Dogmas
Authors: Varsha Gandhi, Rakesh Jalali
Journal: Cancer Research (2017)

In 2016, Tata Memorial Center in Mumbai, India, reached its platinum jubilee milestone (75 years), which was celebrated with conferences. The first of these was entitled, "A Conference of New Ideas in Cancer - Challenging Dogmas." The aim of the conference was to take an honest appraisal about the state of cancer research today, to debate "currently entrenched versus contrarian viewpoints" and to reflect upon whether the current research and therapeutic strategies are appropriate and whether resources are being optimally utilized in meaningful ways. Below, we describe major highlights of this meeting. Cancer Res; 77(2); 234-7. ©2017 AACR.
P2.01-067 The Relevance of CEA and CYFRA21-1 as Predictive Factors in Nivolumab Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
Authors: Maria Giovanna Dal Bello, Rosangela Filiberti, Erka Rijavec, Carlo Genova, Giulia Barletta, Giovanni Rossi, Federica Biello, Roberta Distefano, Anna Maria Orengo, Angela Alama, Simona Coco, Irene Vanni, Michele Mussap, Francesco Grossi
Journal: Journal of Thoracic Oncology (2017)
P2.04-002 The Efficacy of Postoperative Radiotherapy against Thymic Epithelial Tumors According to Masaoka Staging and WHO Classification
Authors: Kai Obayashi, Kimihiro Shimizu, Toshireru Nagashima, Yoichi Ohtaki, Seshiru Nakazawa, Yoko Azuma, Misaki Iijima, Takayuki Kosaka, Toshiki Yajima, Akira Mogi, Hiroyuki Kuwano
Journal: Journal of Thoracic Oncology (2017)
Synergistic Cytotoxic Effects of a Combination of a Novel Tyrosine Kinase Inhibitor AMN107 and Histone Deacetylase Inhibitor LBH589 Against Bcr-Abl Expressing Human Leukemia Cells.
Authors: Anna Scuto, Srinivas Annavarapu, Purva Bali, Molly McCullers, Warren Fiskus, Abdelmoughite Mouttaki, Fei Guo, Celia Sigua, Gautam Sondarva, Peter Atadja, Paul Manley, Kapil N. Bhalla
Journal: Blood (2004)
P181 Transition arrangements for young adults with asthma: uk national survey
Authors: CWJ Lee, BR Patel, T Nagarajan, H James, H Burhan, GH Jones
Journal: Thorax (2016)

<h3>Introduction</h3> Transition of young adults (YA) from specialist paediatric to adult services is an active process that requires specific management and planning and does not merely represent the transfer of care as a single event. In other chronic diseases (e.g. Cystic Fibrosis; T1DM) it is well acknowledged that clinical outcomes improve when this process is well organised and where this is lacking the risk of non-adherence to treatment and loss of disease control increases. BTS guidelines<sup>1</sup> clearly recommend a coordinated approach when transitioning YA in an asthma setting. Despite the importance of this process, little information is available on transition arrangements in asthma services. <h3>Methods</h3> An online survey was sent to 105 trusts with adult asthma services in all parts of the UK to establish their transition arrangements. <h3>Results</h3> Of the 43 responding centres (District General Hospital n = 20), only 60% had a designated lead (n = 26) and less than half made any form of specific arrangements for transition (n = 18). University Hospital trusts were more likely to have transitional care arrangements in place (n = 11/22) than District General Hospitals (n = 6/20). In those centres that did run joint clinics (n = 16), in the majority of cases this only involved adult team members attending paediatric clinics (n = 10). Most centres (n = 25) expected ≤5 patients to transition each year and over 90% (n = 37) did not initiate contact with YA until they were ≥15 yrs old. Only a third of centres delayed transition if YA were not perceived to be ready (n = 15) or remained in full time education (n = 15). Overall less than a third of respondents (n = 13) were satisfied with their transition arrangements. <h3>Conclusions</h3> Our survey reveals for the first time the wide variation in approaches to transition in asthma clinics across the UK. Our data suggests that currently most centres are not committing the recommended resources towards this process, no doubt hampered in part by the relatively small numbers of young adults with asthma transitioning each year. <h3>Reference</h3> British Thoracic Society. <i>BTS/SIGN Asthma guideline</i>. 2014. https://www.brit-thoracic.org.uk/document-library/clinical-information/asthma/btssign-asthma-guideline-2014/ (accessed 28 June 2016).
Granulocyte Colony-Stimulating Factor and Acute Myocardial Infarction
Authors: Dietlind Zohlnhöfer, Ilka Ott, Adnan Kastrati, Albert Schömig
Journal: JAMA (2006)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Chronic Myeloid Leukemia (CML) in Childhood - Results of the Multicenter-Trial CML-paed.
Authors: Meinolf Suttorp, Alexander Claviez, Yvonne Martiniak, Thomas Klingebiel, Dietrich Niethammer, Helmut Gadner, Chris Peters, Hartmut Kabisch, Bernhard Kremens, Felix Zintl, Guenter Henze, Ulrich Goebel
Journal: Blood (2004)
Norovirus infections in England hit highest rate for five years
Authors: Susan Mayor
Journal: BMJ (2017)

The number of people testing positive for norovirus infection, the so called “winter vomiting bug,” has reached its highest level for five years, figures from Public Health England have shown.1

The number of laboratory reports of norovirus for this winter season, July to December 2016, was 2602. This is 8% higher than the average number of documented cases (2403) over the five winter seasons from 2011-12 to 2015-16, and it …
MA10.10 [18F]-FDG-PET/CT Early Response to Nivolumab in NSCLC
Authors: Dimitri Bellevre, Gegory Petyt, Guillaume Collet, Claude Hossein-Foucher, Simon Baldacci, Anne Baranzelli, Franck Semah, Alexis Cortot
Journal: Journal of Thoracic Oncology (2017)
High Rate of Survival in Transformed Lymphoma after Autologous Stem Cell Transplant (ASCT): Pathologic Analysis and Comparison with De Novo DLBCL.
Authors: Stephen S. Smith, Brian Bolwell, Anjali Advani, Steven Andresen, Josephine Chan, Robert Dean, Eric Hsi, Matt Kalaycio, Brad Pohlman, Lisa Rybicki, Ronald Sobecks, John Sweetenham
Journal: Blood (2008)
Spontaneous Pulmonary Hypertension in Transgenic Sickle Cell Mice - Hemodynamics and Histology Suggest Abnormal Nitric Oxide Production and Scavenging.
Authors: Lewis L. Hsu, Hunter C. Champion, Elizabeth Manci, Bhalchandra Diwan, Daniel Schimel, Audrey Cochard, Xunde Wang, J. D. Holtzclaw, Alan Schechter, Constance T. Noguchi, Mark Gladwin
Journal: Blood (2005)
Biopsychosocial model of disease: 40 years on. Which way is the pendulum swinging?
Authors: Gwendolen Jull
Journal: British Journal of Sports Medicine (2017)

The biopsychosocial model came to prominence in 1977 when it was introduced by Engel1 who argued against the reductionist biomedical model of disease and for concomitant consideration of behavioural, psychological and social dimensions in understanding a person's medical condition. This conceptual model was initially proposed within the field of psychiatry, but it quickly expanded to other fields of medicine. In 1987, Waddell2 proposed a new conceptual model for the treatment of chronic low back pain, which encompassed the biopsychosocial framework and brought it into the sphere of musculoskeletal disorders.

Few would question the merits of the model as it is unreasonable to separate the person and their personal circumstances from their medical condition and to regard physical and psychosocial components as independent entities. The model has relevance for all musculoskeletal pain states, acute or chronic, but it has been most widely advocated in chronic pain disorders.3 It has wide perspectives and promotes consideration and evaluation of all potential biological, psychological and social determinants of a …
P298 Tiotropium/olodaterol therapy provides symptomatic benefits irrespective of prior maintenance treatment: post hoc analyses of the otemto® studies
Authors: R Abrahams, GT Ferguson, L Bjermer, L Grönke, F Voß, D Singh
Journal: Thorax (2016)

<h3>Rationale</h3> The combination of tiotropium (T), a long-acting muscarinic antagonist (LAMA), plus olodaterol (O), a long-acting β<sub>2</sub>-agonist (LABA), is approved for once-daily maintenance treatment of COPD. The randomised, double-blind, Phase IIIb OTEMTO<sup>®</sup> 1 and 2 studies (NCT01431274; NCT01431287) showed improvements in quality of life and lung function after 12 weeks’ treatment with T/O compared to T alone or placebo in patients with moderate to severe COPD. This <i>post hoc</i> analysis investigated whether previous maintenance treatment with a long-acting bronchodilator or inhaled corticosteroid (ICS) influenced symptomatic benefits of T/O. <h3>Methods</h3> Patients aged ≥40 years received T/O 2.5/5 µg, T/O 5/5 µg, T 5 µg or placebo once daily for 12 weeks via Respimat<sup>®</sup> inhaler. St George’s Respiratory Questionnaire (SGRQ) total score was a primary end point, alongside lung function (FEV<sub>1</sub> area under the curve from 0–3 hours and trough FEV<sub>1</sub> responses). Secondary end points included Mahler Transition Dyspnoea Index (TDI) focal score. Salbutamol/albuterol was provided as rescue medication and use was recorded in an e-diary. We report comparisons between T/O 5/5 µg, T 5 µg and placebo. <h3>Results</h3> Of the 1621 patients evaluated, 943 had received prior maintenance treatment (66.7% LABA; 59.4% LAMA; 64.5% ICS) and 678 had not. Similar improvements in mean SGRQ total score were observed with T/O compared to T and placebo, respectively, in patients receiving prior maintenance treatment (−2.02 and −4.59 units) and those without (−2.20 and −4.78 units) (Table). TDI focal scores improved with T/O compared to T and placebo, respectively, in patients receiving prior maintenance treatment (0.60 and 1.87 units) and those without (0.60 and 1.33 units) (Table). Patients with and without prior maintenance treatment demonstrated similar improvements in daytime and night-time rescue medication use and lung-function improvements with T/O compared to T and placebo. <h3>Conclusions</h3> T/O provides symptomatic benefits as demonstrated by improvements in SGRQ score, TDI focal score and decreased rescue medication use compared to placebo and T, independent of previous maintenance treatment. These findings suggest T/O is beneficial over monotherapy when used as first COPD maintenance treatment. <h3>Funding</h3> Boehringer Ingelheim. Please refer to page A273 for declarations of interest in relation to abstract P298.
The Retinoid Derivative Drug, Acitretin, Modulates CD38 Expression on MEC-1 Cells and Primary Chronic Lymphocytic Leukemia (CLL) Cells and Reduces Migration in Response to the Chemokine CXCL12
Authors: Sally Elsir Mohammed, Philip Murphy, John Quinn, Patrick Thornton, Stephen Bergin, Bryan Hennessy
Journal: Blood (2015)
Identification of Survival Critical Genomic Gains or Losses in Myeloma (MM) Using Array-Comparative Genomic Hybridization (aCGH).
Authors: Wee J. Chng, Tae-Hoon Chung, Jonathan J. Keats, Angela Baker, P. Leif Bergsagel, John Carpten, Rafael Fonseca
Journal: Blood (2007)
Low Incidence of Severe Mucositis After Myeloablative, HLA-Matched Bone Marrow Transplantation and High Dose, Post-Transplantation Cyclophosphamide
Authors: Wendy Ying, Tracy T. Douglas, Nadira Durakovic, Sallie Brovitz-Palmer, Lindsey Lombardi Thomas, Richard J. Jones, Leo Luznik, Ephraim J. Fuchs
Journal: Blood (2011)